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Vaccines, analgesia and antibiotics embody some of the most enduring 
therapeutic breakthroughs that have transformed medicine. Building on such 
fine paradigms of biomedical innovation, the evolution of technologies has 
increasingly sparked spectacular advances across the continuum of wellness 
and disease spanning medical and surgical specialties. Discovery science - 
fueled by government and private sector resources - has systematically 
instituted the principles of modern healthcare delivery ensuring that medical 
practice is based on up-to-date scientific evidence. The harmony between 
science, technology, and resources has culminated in a golden age of 
discovery and translation, eradicating infections, curing cancers, and palliating 
endocrine and metabolic diseases. Indeed, proven therapeutic and preventive 
approaches have progressively moved into everyday practice. 
The success of the science-medicine union has spurred public and private 
sector investments, further fueling the engine of discovery and enabling 
technology. This integration produced the new biology, enabling advances in 
technology platforms to offer unprecedented opportunities in disease 
prediction, prevention, and even cure beyond the reach of traditional 
healthcare solutions. Modern science offers outstanding opportunities to probe 
the innermost workings of the human body, and to understand how events at 
the subcellular and molecular levels influence the functioning and integrity of 
the individual as a whole.1,2 Remarkable progress is being made in 
understanding the molecular, genetic, and cellular origins of disease, and 
opportunities now exist to uncover practical uses for this new knowledge, 
particularly in the realm of personalized medicine.3,4  
Unexpectedly, however, acceleration in enabling technologies and the 
resultant insights into basic pathophysiological mechanisms has outstripped the 
capacity of current scientific and clinical structures to efficiently manage their 
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translation into new paradigms to improve the health and quality of life of 
individuals, communities and populations.5 In that context, federally-funded 
research programs have produced hundreds, if not thousands, of new disease-
related molecular targets that represent potential diagnostic and therapeutic 
targets for tailored disease management.6 Unfortunately, their applications 
remain only a distant promise, reflecting a limited capacity in structures, 
resources and the specialized workforces required for their translations into new 
healthcare paradigms. Compounding these challenges is the reality that 95% of 
promising therapies brought into clinical development in the private sector 
ultimately fail because of limitations in efficacy or unacceptable toxicities. 
Further research is needed to identify, measure, and validate targets and 
pathways that have been detected in basic studies, and then to develop new 
clinical applications and rigorously evaluate their effectiveness and safety. 
Indeed, further understanding of the translation process itself must occur to 
expedite and expand the adoption of biomedical advances into clinical 
practice and individual health behaviors. 
Recognition of the need to rebalance the equation, and bring translation 
into register with the power, progress, and pace of discovery science and 
associated enabling technologies is reflected in the recent enactment of the 
Cures Acceleration Network (CAN), legislation that seeks to bridge the chasm 
between basic scientific discoveries and new health treatments.7 Part of the 
Patient Protection and Affordable Care Act, CAN mandates that the National 
Institutes of Health (NIH) advance the development of highly needed cures by 
reducing barriers between research discovery and translation. The CAN 
provisions grant NIH flexibility to carry out therapeutic development projects and 
underscore the expectations of Congress and the American public that the NIH 
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will have a catalytic role in moving scientific discovery along the continuum that 
ultimately creates advances in human health. 
The leadership of the NIH, embracing this mandate to accelerate 
translation inherent in CAN, charged its Scientific Management Review Board 
with defining a path forward to rebalance the equation.  Those deliberations 
resulted in the near-unanimous suggestion by the SMRB to constitute a new 
National Center for Advancing Translational Sciences.  The charge of this new 
Center will include: 
• Advancing novel molecular discoveries across the translational Valley 
of Death into promising technologies with a more favorable risk-
benefit ratio that will appeal to the private sector for further 
development into novel modalities that change patient care.8 
• Consolidating the considerable resources already existing in NIH 
programs and cores that can facilitate the development of molecular 
science across the translational continuum.  These will include the 
Molecular Libraries Program (MLP) which offers access to high 
throughput screening capabilities and libraries of compounds useful 
for research and as therapeutics. For example, the Chemical 
Genomics Center, part of MLP, provides a robotic, high throughput 
screening system and a library of >350,000 small molecules to 
interrogate fundamental cellular mechanisms. The Therapeutics for 
Rare and Neglected Diseases program provides resources for 
preclinical drug development centered on rare disorders with limited 
commercial interest. Finally, Clinical and Translational Science Awards 
offer a linked nationwide network of institutions providing the 
infrastructure and workforce to advance the development of 
therapeutic through patient and community-based studies.9 
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• Nucleating interactions between public and private sectors that 
maximize the utility of technology resources, distribute risk to lower 
barriers to commercialize diagnostics and therapeutics, and 
orchestrate the appropriate organizational transitions (e.g., 
academic-government, government-pharmaceutical company) 
along the developmental continuum to optimize translational 
efficiencies. 
• Leading the development of the next generation of clinical and 
translational investigators. Rebalancing the equation to equilibrate 
discovery and translational science will necessitate developing a 
cadre of investigators fluent in the lexicons of the laboratory and 
clinic.10 They must understand the widely different paradigms 
underlying laboratory-based experimentation and clinical diagnosis 
and therapy, enabling integration of these structures in which critical 
unmet gaps in patient care drive the evolution of science. Moreover, 
they will require a transformation in professional culture that incents 
science practiced as part of multidisciplinary teams, rather than the 
current silos which reward individual contributions.11,12 
The creation of the National Center for Advancing Translational Sciences 
evidences a broad contemporary vision of the investigational continuum from 
molecules, to patients and populations. It anticipates the evolution of translation 
from a science focused on new therapeutic modalities for disease palliation, to 
the assessment of risk and the science of wellness and disease prevention.13,14 
The Center will leverage existing and emerging resources to maximize 
productivity in the form of better health and quality of life. Moreover, it brings 
divergent stakeholders to the table, across traditionally insular communities of 
practice, and invests them in a public-private partnership and an envisioned 
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future in which science is the engine driving translation and clinical 
development to amplify efficiencies and reduce risks associated with improving 
patient care. 
While this bold step marks a sea change in the way the science of 
translation is conducted in the United States, the leaders of the NIH continue 
their forward-looking vision, anticipating challenges that could attenuate the 
impact of the new center. Those considerations include: 
• The science of translation will maximally benefit from the broadest 
participation of the widest communities of practice. Teams of clinical 
and translational investigators will cut across disciplines, guilds, and 
cultures where individual knowledge and skill sets are valued for their 
potentiation of the greater goals. Teams will include physicians, 
scientists, engineers, pharmacists, therapists and others contributing to 
the generation of new insights, their operationalization into new 
modalities of healthcare, and their dissemination across populations, 
communities, and the global landscape. Conversely, the science of 
translation cannot be the purview of any specific clinical and scientific 
discipline. Indeed, restricting the science of translation to ownership by 
a single discipline jeopardizes the success of the entire enterprise. 
• The science of drug development traditionally has been the focus of 
the biopharmaceutical industry, which has been the primary source of 
new diagnostic and therapeutic modalities for managing patients.15,16 
Even in the face of their considerable innovation and expertise, the 
success rate for new drugs is less then 5%, and success is associated 
with a price tag topping $1 billion. One goal of the new center will to 
accelerate the translation of the hundreds of new targets into 
promising therapeutic compounds in early clinical trials. The goal is to 
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“de-risk” these targets and agents, to make them more attractive to 
biopharmaceutical partners, who will advance them into late stage 
trials in anticipation of regulatory approval and marketing. One central 
consideration in this model is how the new center and its partners will 
“beat the odds” inherent in drug development. Indeed, while the 
pharmaceutical industry has the deepest expertise in this field, invests 
as much, if not more, capital resources into research as does the NIH, 
and is powerfully motivated by profit and investor satisfaction for 
success, the success rate remains very low. The architects of the new 
center are considering novel models, paradigms, and collaborations 
that increase the success rate required to accommodate enhanced 
throughput represented by translation of the backlog of new markers 
and targets. 
• A correlative consideration is the measurement of success in this new 
endeavor, a core consideration for the new center. While the goals for 
enhancing translational science are clear, the methods to measure 
enhancement are less straightforward.  Logically, the gold standard 
would be the number of new therapeutic agents being translated into 
patient care algorithms. However, this is particularly complicated by 
the very long timelines inherent in the drug development process. 
Indeed, it can take up to 15-20 years for a new entity to move from 
discovery into late stage clinical trials and regulatory submission. More 
proximal surrogate metrics, for example numbers of new therapeutics 
advanced into clinical trials, suggest activity in the system but do not 
address whether this activity is optimally productive, or is even 
commensurate with the track record of the pharmaceutical industry, 
acknowledged leaders in this field. Thus, it will not be sufficient to show 
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metrics of utility or traditional markers of interim performance. Rather, 
the challenge will be to identify markers of performance that correlate 
closely with ultimate success. This is not a trivial task and the 
biopharmaceutical industry has been chasing this ideal, without 
apparent success. 
• New center activities are decidedly focused on the earliest stages of 
the translational continuum. Indeed, the focus for this organization is on 
discovery, target validation, preclinical animal models, and early stage 
clinical trials, including T1 translation in which safety and tolerability are 
established, and T2 translation, in which efficacy is first explored.1,17 
However, equally important are T3 and T4 translation. In T3 translation, 
new knowledge surrounding the clinical application of discoveries 
revealed in T1 and T2 must be disseminated into community 
practices.1,17 This critical step, and the associated gap and essential 
unmet clinical need, was only revealed once it was recognized that 
breakthrough discoveries failed to optimally translate into community 
practice. This gap in dissemination represents one primary limitation 
restricting the application of new discoveries to global populations. 
While T1 and T2 translation involve well-established skill sets and 
processes, T3 challenges the enterprise to innovate concepts and 
methods to disseminate new clinical knowledge for integration into 
practice, including health services research, community-based 
participatory research, and comparative effectiveness research. 
Beyond incorporating evidence-based knowledge into clinical 
practice, T4 translation seeks to advance scientific knowledge beyond 
algorithms of palliation treating established disease, to paradigms of 
disease prevention through lifestyle and behavioral alterations in 
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communities and populations. It is at this stage of translation that the 
enterprise undergoes a strategic evolution from a medical model of 
clinical practice (intervention), to a public health model of disease 
management (prevention). Here, the public health model focuses on 
information and education programs that eliminate deleterious 
behaviors at the community and population levels that produce 
disease susceptibility.18 In essence, T4 research seeks to move health 
practices established in T3 into population health impact, associated 
with improved disease prevention and reduced costs for medical care. 
Skill sets central to T4 translation include the well-established paradigms 
for public health and population research and emerging areas 
including outcomes research. Together, these considerations highlight 
the essential nature of the entire T1-T4 translational continuum to 
accelerate discovery into new paradigms for the management of 
patients and communities. 
Formation of the new National Center for Advancing Translational 
Sciences represents a critical exponential step in the evolution of the science of 
translation.19,20 It amalgamates national resources and programs whose 
centralization and integration will facilitate discovery and early development. It 
will nucleate public-private partnerships that hold the promise of accelerating 
new insights in molecular mechanisms underlying pathophysiology into novel 
diagnostics and therapeutics. Moreover, it will create a career path in clinical 
and translational science and medicine that will prepare the next generation of 
skilled investigators invested the culture of team science. This great promise and 
potential can only be realized in the context of solving the great challenges that 
work to minimize the impact of translation on the healthcare of populations: 
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inclusion of broad communities of practice, failure rates in drug development, 
metrics of performance, and covering the translational medicine continuum.  
The new National Center can be viewed as one bold example of visionary 
disruptive innovation, in which traditional structures are reconfigured in 
unanticipated ways to achieve exponential evolution in a field. In that context, 
the new Center provides an unprecedented opportunity to recast science and 
medicine in response to the evolving needs of our patients while sustaining 
affordable healthcare. Here, translational medicine represents the critical next 
evolutionary step in realizing the clinical value of the new biology in order to 
drive discovery into personalized health care solutions. By offering paradigms to 
predict, prevent, treat and cure disease, translational medicine will be poised to 
enable application of transformative diagnostics, prognostics and therapies that 
promote longitudinal wellness and advance health care for individuals and 
populations. The ultimate mandate for the new National Center is to secure 
early adoption of the integration of discovery innovation into clinical practice in 
response to patients and society who seek new products and services to 
address unmet needs. 
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